In a subsequent proof of concept study, we found that 50% of MS patients exhibited enhanced peripheral blood monocyte TLR2-stimulated responses, further suggesting deficient regulation of TLR2 responses in these patients [17]. Here, TLR2 is linked to myeloid sarcoma.